CBU
ALNY icon

CIBC Bancorp USA’s Alnylam Pharmaceuticals ALNY Stock Holding History

CIBC Bancorp USA’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.3M Sell
163,733
-5,298
-3% -$1.6M 0.06% 260
2026
Q1 		$55.9M Buy
+169,031
New +$57.5M 0.08% 206
2025
Q3 		$2.13M Buy
+4,675
New +$1.9M 0.01% 577

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CIBC Bancorp USA's ALNY Position: Q2 2026 in Review

CIBC Bancorp USA reduced its Alnylam Pharmaceuticals (ALNY) stake by 3.1% in Q2 2026, selling an estimated $1.6M and leaving 163,733 shares worth $49.3M. The position accounts for 0.06% of the portfolio, ranked #260.

CIBC Bancorp USA first reported a position in ALNY in Q3 2025 and has held it in 3 quarters since. The position peaked at $55.9M in Q1 2026. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • CIBC Bancorp USA held 163,733 shares of Alnylam Pharmaceuticals worth $49.3M as of Q2 2026.
  • CIBC Bancorp USA sold 5,298 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $1.6M.
  • Alnylam Pharmaceuticals made up 0.06% of CIBC Bancorp USA's portfolio in Q2 2026, its #260 holding.
  • CIBC Bancorp USA first reported a position in Alnylam Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • CIBC Bancorp USA's Alnylam Pharmaceuticals position peaked at $55.9M in Q1 2026.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.